Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer

Torng Sen Lin, Shiow Her Chiou, Liang Shun Wang, Hsuan Hua Huang, Shu Fen Chiang, Alex Y H Shih, Y. A Lin Chen, Chih Y I Chen, Chung Ping Hsu, Nan Yung Hsu, Ming Chih Chou, Shou Jen Kuo, Kuan Chih Chow

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

By combining suppression subtractive hybridization and microarray to examine gene expressions between metastatic and non-metastatic non-small cell lung cancer (NSCLC), we have identified differential expression spectra of matrix metalloproteinases (MMP). Among MMPs, expressions of MMP-13, -14, -15 and -24 decreased, those of MMP-9, -11, -12, -16, -17, -19 and -23B did not change, and those of MMP-1, -2, -7, -8 and -10 increased dramatically. Overexpressions of MMP-1, -2, -7 and -10 were confirmed by reverse transcription-polymerase chain reaction. In this study we further assessed the clinical significance of MMP-1, -2, -7 and -10. Specimens from 472 patients with completely resected NSCLC were examined by immunohistochemistry. The median follow-up period was 38 months (range, 2-113 months). Overexpression of MMP-1 was observed in 72.9% (n=344) of 472 patients, that of MMP-2 was 77.9% (n=352), MMP-7 63.3% (n=299) and that of MMP-10 was 27.1% (n=128). For patients with lymph node metastasis, MMP-1 and -2 overexpressions were not only independent prognostic factors for unfavorable outcome, but also associated with decreased survival (p=0.0015, and p=0.011 respectively). The present study showed that MMP expression spectrum in NSCLC was heterogeneous: expression of some MMP increased, some unchanged, while some decreased. Therefore, it should be worth determining MMP expression pattern as a regimen reference for NSCLC patients who were scheduled to receive MMP inhibitor, which was class-specific, as adjuvant therapeutic agent.

Original languageEnglish
Pages (from-to)717-723
Number of pages7
JournalOncology Reports
Volume12
Issue number4
Publication statusPublished - Oct 2004
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 1
Matrix Metalloproteinase 2
Matrix Metalloproteinases
Non-Small Cell Lung Carcinoma
Matrix Metalloproteinase 10
Matrix Metalloproteinase 11
Matrix Metalloproteinase 7
Matrix Metalloproteinase 13
Matrix Metalloproteinase 14
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinase 9
Reverse Transcription
Lymph Nodes
Immunohistochemistry
Neoplasm Metastasis
Gene Expression
Polymerase Chain Reaction
Survival

Keywords

  • Immunohistochemistry
  • Microarray
  • Prognosis
  • RT-PCR
  • Suppression subtractive hybridization

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lin, T. S., Chiou, S. H., Wang, L. S., Huang, H. H., Chiang, S. F., Shih, A. Y. H., ... Chow, K. C. (2004). Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncology Reports, 12(4), 717-723.

Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. / Lin, Torng Sen; Chiou, Shiow Her; Wang, Liang Shun; Huang, Hsuan Hua; Chiang, Shu Fen; Shih, Alex Y H; Chen, Y. A Lin; Chen, Chih Y I; Hsu, Chung Ping; Hsu, Nan Yung; Chou, Ming Chih; Kuo, Shou Jen; Chow, Kuan Chih.

In: Oncology Reports, Vol. 12, No. 4, 10.2004, p. 717-723.

Research output: Contribution to journalArticle

Lin, TS, Chiou, SH, Wang, LS, Huang, HH, Chiang, SF, Shih, AYH, Chen, YAL, Chen, CYI, Hsu, CP, Hsu, NY, Chou, MC, Kuo, SJ & Chow, KC 2004, 'Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer', Oncology Reports, vol. 12, no. 4, pp. 717-723.
Lin TS, Chiou SH, Wang LS, Huang HH, Chiang SF, Shih AYH et al. Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncology Reports. 2004 Oct;12(4):717-723.
Lin, Torng Sen ; Chiou, Shiow Her ; Wang, Liang Shun ; Huang, Hsuan Hua ; Chiang, Shu Fen ; Shih, Alex Y H ; Chen, Y. A Lin ; Chen, Chih Y I ; Hsu, Chung Ping ; Hsu, Nan Yung ; Chou, Ming Chih ; Kuo, Shou Jen ; Chow, Kuan Chih. / Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. In: Oncology Reports. 2004 ; Vol. 12, No. 4. pp. 717-723.
@article{74c8ac7c87d44dba847a9e8749965643,
title = "Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer",
abstract = "By combining suppression subtractive hybridization and microarray to examine gene expressions between metastatic and non-metastatic non-small cell lung cancer (NSCLC), we have identified differential expression spectra of matrix metalloproteinases (MMP). Among MMPs, expressions of MMP-13, -14, -15 and -24 decreased, those of MMP-9, -11, -12, -16, -17, -19 and -23B did not change, and those of MMP-1, -2, -7, -8 and -10 increased dramatically. Overexpressions of MMP-1, -2, -7 and -10 were confirmed by reverse transcription-polymerase chain reaction. In this study we further assessed the clinical significance of MMP-1, -2, -7 and -10. Specimens from 472 patients with completely resected NSCLC were examined by immunohistochemistry. The median follow-up period was 38 months (range, 2-113 months). Overexpression of MMP-1 was observed in 72.9{\%} (n=344) of 472 patients, that of MMP-2 was 77.9{\%} (n=352), MMP-7 63.3{\%} (n=299) and that of MMP-10 was 27.1{\%} (n=128). For patients with lymph node metastasis, MMP-1 and -2 overexpressions were not only independent prognostic factors for unfavorable outcome, but also associated with decreased survival (p=0.0015, and p=0.011 respectively). The present study showed that MMP expression spectrum in NSCLC was heterogeneous: expression of some MMP increased, some unchanged, while some decreased. Therefore, it should be worth determining MMP expression pattern as a regimen reference for NSCLC patients who were scheduled to receive MMP inhibitor, which was class-specific, as adjuvant therapeutic agent.",
keywords = "Immunohistochemistry, Microarray, Prognosis, RT-PCR, Suppression subtractive hybridization",
author = "Lin, {Torng Sen} and Chiou, {Shiow Her} and Wang, {Liang Shun} and Huang, {Hsuan Hua} and Chiang, {Shu Fen} and Shih, {Alex Y H} and Chen, {Y. A Lin} and Chen, {Chih Y I} and Hsu, {Chung Ping} and Hsu, {Nan Yung} and Chou, {Ming Chih} and Kuo, {Shou Jen} and Chow, {Kuan Chih}",
year = "2004",
month = "10",
language = "English",
volume = "12",
pages = "717--723",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer

AU - Lin, Torng Sen

AU - Chiou, Shiow Her

AU - Wang, Liang Shun

AU - Huang, Hsuan Hua

AU - Chiang, Shu Fen

AU - Shih, Alex Y H

AU - Chen, Y. A Lin

AU - Chen, Chih Y I

AU - Hsu, Chung Ping

AU - Hsu, Nan Yung

AU - Chou, Ming Chih

AU - Kuo, Shou Jen

AU - Chow, Kuan Chih

PY - 2004/10

Y1 - 2004/10

N2 - By combining suppression subtractive hybridization and microarray to examine gene expressions between metastatic and non-metastatic non-small cell lung cancer (NSCLC), we have identified differential expression spectra of matrix metalloproteinases (MMP). Among MMPs, expressions of MMP-13, -14, -15 and -24 decreased, those of MMP-9, -11, -12, -16, -17, -19 and -23B did not change, and those of MMP-1, -2, -7, -8 and -10 increased dramatically. Overexpressions of MMP-1, -2, -7 and -10 were confirmed by reverse transcription-polymerase chain reaction. In this study we further assessed the clinical significance of MMP-1, -2, -7 and -10. Specimens from 472 patients with completely resected NSCLC were examined by immunohistochemistry. The median follow-up period was 38 months (range, 2-113 months). Overexpression of MMP-1 was observed in 72.9% (n=344) of 472 patients, that of MMP-2 was 77.9% (n=352), MMP-7 63.3% (n=299) and that of MMP-10 was 27.1% (n=128). For patients with lymph node metastasis, MMP-1 and -2 overexpressions were not only independent prognostic factors for unfavorable outcome, but also associated with decreased survival (p=0.0015, and p=0.011 respectively). The present study showed that MMP expression spectrum in NSCLC was heterogeneous: expression of some MMP increased, some unchanged, while some decreased. Therefore, it should be worth determining MMP expression pattern as a regimen reference for NSCLC patients who were scheduled to receive MMP inhibitor, which was class-specific, as adjuvant therapeutic agent.

AB - By combining suppression subtractive hybridization and microarray to examine gene expressions between metastatic and non-metastatic non-small cell lung cancer (NSCLC), we have identified differential expression spectra of matrix metalloproteinases (MMP). Among MMPs, expressions of MMP-13, -14, -15 and -24 decreased, those of MMP-9, -11, -12, -16, -17, -19 and -23B did not change, and those of MMP-1, -2, -7, -8 and -10 increased dramatically. Overexpressions of MMP-1, -2, -7 and -10 were confirmed by reverse transcription-polymerase chain reaction. In this study we further assessed the clinical significance of MMP-1, -2, -7 and -10. Specimens from 472 patients with completely resected NSCLC were examined by immunohistochemistry. The median follow-up period was 38 months (range, 2-113 months). Overexpression of MMP-1 was observed in 72.9% (n=344) of 472 patients, that of MMP-2 was 77.9% (n=352), MMP-7 63.3% (n=299) and that of MMP-10 was 27.1% (n=128). For patients with lymph node metastasis, MMP-1 and -2 overexpressions were not only independent prognostic factors for unfavorable outcome, but also associated with decreased survival (p=0.0015, and p=0.011 respectively). The present study showed that MMP expression spectrum in NSCLC was heterogeneous: expression of some MMP increased, some unchanged, while some decreased. Therefore, it should be worth determining MMP expression pattern as a regimen reference for NSCLC patients who were scheduled to receive MMP inhibitor, which was class-specific, as adjuvant therapeutic agent.

KW - Immunohistochemistry

KW - Microarray

KW - Prognosis

KW - RT-PCR

KW - Suppression subtractive hybridization

UR - http://www.scopus.com/inward/record.url?scp=16644397431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644397431&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 717

EP - 723

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -